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Methods
Search Strategy
Electronic literature search completed using online databases: PubMed, CINAHL, and EMBASE. 
Complete search strategy: (deaf* OR hearing loss) AND genetic* AND aminoglycoside*
No language or date restrictions were applied. 
Study Selection
An initial screening of the articles was completed through an evaluation of titles and years of publication. 
Following the first round of exclusions and removal of duplicates, 243 articles 
remained for review. 
Abstracts of remaining articles were then independently assessed by three 
researchers.  All articles were assessed independently by two of the researchers, 
with an inter-rater reliability of 75%.  All researchers participated in resolving 
disagreements.
Critical Appraisal
Critical appraisals were carried out individually by the three researchers. Twenty 
percent (3/14) of the articles were evaluated by two researchers as a metric of 
inter-rater agreement. LEGEND Appraisal Forms from Cincinnati Children’s 
Hospital were referenced for this process (http://www.cincinnatichildrens.org/s
ervice/j/anderson-center/evidence-basedcare/legend/). Information on study 
design, sample size, population of interest, prevalence (results), and limitations 
was gathered from each study and used to make a final determination on the 
level of evidence.
Discussion
While the aim of the current study was to quantitatively assess the role of the A1555G mutation in aminoglycoside ototoxicity, variability in study designs and
outcome measures prevented a meta-analysis of this nature. Nonetheless, results generally support an increased risk of hearing loss following aminoglycoside
exposure in individuals with the A1555G mutation.
Three major categories emerged from the current review; studies assessing specific ethnicities, clinical populations involving specific diseases, and neonates. Articles
from Thailand, China, Japan, and the United States were included for review, and it was found that the frequency of the A1555G mutation differs across ethnicities. It
is important to note that the studies evaluated did not address regional differences in how frequently aminoglycosides are prescribed, which is an important
confounding variable to consider when assessing aminoglycoside ototoxicity across ethnic groups. Studies evaluating at risk clinical populations, such as those with
cystic fibrosis and leukemia, and neonates support the need for increased monitoring for genetic susceptibility to ototoxic hearing loss .
This study provides evidence of the variability in prevalence of the A1555G mutation among patients with ototoxic hearing loss and may support an increased risk for
hearing loss among those with the A1555G mutation following aminoglycoside exposure.
Future Implications
Future studies on this topic should aim to include larger samples sizes and implement replicable study designs. Comparing audiologic outcomes in individuals receiving
aminoglycosides with and without the A1555G mutation using a controlled study design would allow for a more direct assessment of the effect of this genetic variant.
Ototoxic hearing loss refers to a decline in hearing sensitivity resulting from drug-induced damage to the inner ear. Ototoxicity often presents as a symmetric,
high-frequency hearing loss, although audiogram shape and severity is highly variable across individuals. Over 100 classes of drugs have been described as
ototoxic, the most common of which include loop diuretics, platinum-based chemotherapy drugs, and aminoglycosides (Mudd, 2016).
Aminoglycosides are a class of antibiotics that are used in the treatment of gram-negative bacterial infections. The oto- and nephrotoxic properties of
aminoglycosides have been well-documented. Consequently, these medications are typically reserved for life-threatening infections in the United States and
other developed countries. Examples of clinical use include treating chronic lung infections in cases of cystic fibrosis and combating sepsis in preterm infants.
Aminoglycosides are more routinely prescribed in developing countries due to their low-cost and high efficacy.
In recent decades, advancements in pharmacogenetics have sparked interest in the effect of genetics on susceptibility to aminoglycoside ototoxicity. The AI555G
mitochondrial gene mutation is one genetic variant that has received significant investigative attention. Previous research has suggested that individuals who
carry the A1555G mutation are more susceptible to aminoglycoside-induced hearing loss relative to the general population (Jing et al., 2014).
Ototoxic hearing loss is often irreversible and, like all forms of hearing impairment, can have detrimental effects on language, cognition, social development, and
quality of life. Careful audiologic monitoring of patients at risk for ototoxic hearing loss is vital to reducing these negative outcomes. If associated with
increased risk of ototoxic hearing loss, identification of the A1555G mutation calls for more frequent monitoring and, when possible, reduction in exposure to
aminoglycosides. Understanding the risk factors of ototoxic hearing loss in combination with specific genetic makeups will aid prevention and timely
intervention in this clinical population. The aim of this project was to conduct a systematic review on the role of the A1555G mitochondrial mutation in
aminoglycoside ototoxicity.
Exclusion Criteria
Published prior to completion of the Human Genome Project (2003)
Evaluation of ototoxic effects of cisplatin/carboplatin or loop diuretics
Use of animal subjects
Evaluation of protective agents
Inclusion Criteria
Peer-reviewed studies
Specifically addressing the A1555G mutation
Effect of aminoglycoside antibiotics on hearing loss
Human subjects
Citation Study 
Design
Population 
studied
Sample 
Size
Results Level of Evidence
Al-Malky
(2014)
Case Report CF patients N=2* 3% (2/66) CF patients had A1555G; one subject severe-to-profound hearing loss, while the other had 
hearing WNL
Lesser Quality Case 
Report
Bindu, 
(2008)
Systematic 
Review
N/A N/A Offering evidence of the heterogeneous nature of mtDNA mutations (re: expressivity and penetrance) Lesser Quality 
Systematic Review
Bitner-
Glindzicz
(2010)
Case Report Leukemia 
patients
N=3 Described three unrelated cases of profound hearing loss in the presence of the A1555G mutation 
following aminoglycoside exposure during treatment for acute leukemia 
Lesser Quality Case 
Report
Chaiyasap
(2015)
Case Report Thai family N=5** 4/5 individuals from a Thai family were found to have the A1555G variant; all 4 individuals were 
deafened following exposure to aminoglycosides. 
Lesser Quality Case 
Report
Conrad 
(2008)
Cohort 
Study
CF patients N=157 1.3% (2/157) CF patients with a history of aminoglycoside treatment were found to have the A1555G 
variant. Both individuals had moderate to severe hearing loss.
Lesser Quality Cohort 
Study
Göpel (2014) Cohort 
Study
Preterm infants N=12 0.2% (12/7056) infants were found to have the A1555G mutation. 10 of these 12 infants were treated 
with aminoglycosides; 30% (3/10) referred on their newborn hearing screening
Good Quality Cohort 
Study
Jing (2015) Meta-
analysis
N/A N/A Studied 122 mitochondrial variants across 43 studies; reported a prevalence of 0.013 for the A1555G 
mutation across all populations studied (African, Asian, and European).
Good Quality 
Meta-analysis
Li (2005) Cohort 
Study
Students of 
School for the 
Deaf
N=128 Authors conclude that 48% of cases of hearing loss in this student population are attributable to 
aminoglycoside ototoxicity; within this subset, the frequency of the A1555G mutation is reported to be 
13%.
Lesser Quality Cohort 
Study
Liu (2008). Cohort 
Study
Individuals with 
NSHL
N=498 15.5% of a sample of Chinese individuals with NSHL were found to have the A1555G variant, compared 
to 1.9% a sample from the United States. Among these cases, 64% and 88% reported a history of 
aminoglycoside exposure in China and the United States, respectively.
Good quality Cohort 
Study
Lu (2009). Case Control Japanese 
individuals with 
A1555G
N=221 Authors conclude that aminoglycoside exposure was the most significant environmental factor affecting 
the expression of A1555G mutation in their sample of Japanese Individuals.
Lesser Quality Case 
Control Study
Skou (2014) Case Report 19 m.o. female 
with 
cardiomyopathy
N=1 Described a case of severe hearing loss following aminoglycoside exposure in a 19 m.o. child with the 
A1555G mutation; authors argue for screening of cardiomyopathy patients prior to treatment
Lesser Quality Case 
Report
Tang (2007) Case Report Hans Chinese 
families
7 families Found average penetrance of hearing loss to be 13.6% across 7 Hans Chinese families with the A1555G 
mutation; average penetrance across these families was 5.3% when aminoglycoside exposure was 
excluded.
Lesser Quality Case 
Report
Young (2005) Case Study Chinese families 4 families Authors calculated an average penetrance of hearing loss of 8% across 4 Chinese pedigrees carrying the 
A1555G mutation (including aminoglycoside exposure and NSHL).
Lesser Quality Case 
Study
Zimmerman 
(2013)
Systematic 
Review
NICU Infants N/A Proposes an integrated model of how noise, mitochondrial mutations, and aminoglycoside exposure 
interact to exacerbate hearing loss in NICU infants.
Lesser Quality 
Systematic Review
Results
Included in this study were 2 systematic reviews, 1 meta-analysis, 5 case reports, 4 cohort studies, 1 case study, and 1 case control study. The majority of studies
appraised received a “lesser quality rating.” Studies evaluated the prevalence of hearing loss in the presence of the A1555G mutation within various ethnic groups
and high risk populations, such as preterm infants and cystic fibrosis patients. Results generally support an increased risk of hearing loss following aminoglycoside
exposure in individuals with the A1555G mutation.
Purpose
To evaluate the effect of the A1555G mitochondrial mutation on the risk of hearing loss following aminoglycoside antibiotic exposure. 
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